A Scotland Based Cost-Effectiveness Analysis Of Idelalisib (Zydelig®) In Combination With Rituximab For The Treatment Of Adults With Chronic Lymphocytic Leukaemia Cll)
Abstract
Authors
G Kumar TD Morton A Padhiar R Marsh R Perard